AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
Log in

NASDAQ:ICADiCAD Stock Price, Forecast & News

$9.40
+0.71 (+8.17 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.56
Now: $9.40
$9.44
50-Day Range
$9.02
MA: $11.02
$12.47
52-Week Range
$5.50
Now: $9.40
$15.31
Volume361,905 shs
Average Volume330,069 shs
Market Capitalization$214.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
Current SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.34 million
Book Value$0.26 per share

Profitability

Net Income$-13,550,000.00

Miscellaneous

Employees95
Market Cap$214.95 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.

iCAD (NASDAQ:ICAD) Frequently Asked Questions

How has iCAD's stock been impacted by COVID-19 (Coronavirus)?

iCAD's stock was trading at $11.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ICAD shares have decreased by 15.5% and is now trading at $9.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of iCAD?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for iCAD.

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for iCAD.

How were iCAD's earnings last quarter?

iCAD Inc (NASDAQ:ICAD) issued its earnings results on Monday, May, 11th. The technology company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.07. The technology company had revenue of $6.55 million for the quarter. iCAD had a negative return on equity of 95.94% and a negative net margin of 69.56%. View iCAD's earnings history.

What price target have analysts set for ICAD?

4 brokers have issued 1 year target prices for iCAD's shares. Their forecasts range from $10.00 to $15.00. On average, they expect iCAD's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 43.6% from the stock's current price. View analysts' price targets for iCAD.

Has iCAD been receiving favorable news coverage?

News stories about ICAD stock have trended negative on Friday, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. iCAD earned a news impact score of -2.4 on InfoTrie's scale. They also gave headlines about the technology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news about iCAD.

Who are some of iCAD's key competitors?

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology Group (MRVL), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Fulgent Genetics (FLGT), Intellia Therapeutics (NTLA), InVitae (NVTA), Aptiv (APTV), Alibaba Group (BABA) and Niu Technologies (NIU).

Who are iCAD's key executives?

iCAD's management team includes the following people:
  • Ms. Stacey M. Stevens, Pres (Age 51)
  • Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)
  • Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO (Age 55)
  • Mr. Jonathan Go, Chief Technology Officer (Age 56)
  • Ms. Annette L. Heroux, VP of Admin. (Age 62)

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $9.40.

How big of a company is iCAD?

iCAD has a market capitalization of $214.95 million and generates $31.34 million in revenue each year. The technology company earns $-13,550,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. iCAD employs 95 workers across the globe.

What is iCAD's official website?

The official website for iCAD is www.icadmed.com.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.